NEW YORK (GenomeWeb News) – Cepheid reported after the close of the market on Thursday that its total revenues fell around 3 percent, but its product sales were up 2 percent, for the second quarter of 2009.

The Sunnyvale, Calif.-based molecular diagnostics firm brought in total revenues of $41 million for the three months ended June 30, compared to $42.1 million for the second quarter of 2008. Its product sales increased to $39.6 million from $39 million, while "other" revenues fell to $1.5 million from $3.1 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US National Institutes of Health and the Food and Drug Administration have proposed changing gene therapy oversight, the Associated Press reports.

Nature News reports that the Salk Institute has asked for the scope of a gender discrimination lawsuit brought against it to be narrowed.

CNBC reports that the sequencing startup Veritas aims to sequence individuals who fall at extremes.

In PLOS this week: genotyping of indigenous North African goats, program to simulate evolve and resequencing studies, and more.

Sponsored by

This webinar offers a look at how an advanced genetics laboratory implemented and validated a commercial bioinformatics system to help scale its operations.

Sponsored by
Horizon Discovery

In this webinar, Kevin Balbi, head of bioinformatics at Sarah Cannon Molecular Diagnostics, will discuss the validation of targeted sequencing panels on the Ion Torrent platform using Horizon Discovery’s Tru-Q controls.